MedPath

Efficacy and safety of combination therapy with vildagliptin and nateglinide in type 2 diabetes.

Not Applicable
Conditions
type 2 diabetes
Registration Number
JPRN-UMIN000004010
Lead Sponsor
Department of Medicine, Metabolism and Endocrinology, Juntendo University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) type 1 diabetes 2) patients who has been prescribed sulfonylurea or alpha glucosidase inhibitor 3) patients who have serious liver disease (AST and/or ALT are more than 80IU/L) 4) patients who have serious kidney disease (Serum Cr is more than 1.5mg/dL) 5) patients who have serious heart disease ( patients who have apparent heartfailure or myocardial infarction within 3 months) 6) patients who have serious pancreatic disease 7) patients with cancer 8) anemic patients (Hb is less than 11g/dL) 9) patients with thrombocytepenia (Platelet count is less than 100000/mm3) 10) patients with serious diabetic complications including progressed neutopathy and proliferative retinopathy 11) patietns with serious infection, inflammation, or injuary. pre- or post- operative state 12) patients who have inflammatory bowel disease, ulcer in bowel, ileus and high risk for ileus 13) patinets with chronic bowel diseases which have probability to induce malabsorption syndrome 14) patients who has the disease which is deteriorated with increase of gas in bowel 15) heavy alcohol drinker (patients who drink more than 480mL of Japanese Sake, 2L of beer, 180mL of whisky, 360mL of wine, or 360mL of Shochu per day) 16) patients who are pregnant, hope to be pregnant, or are in lactation period 17) patients who have viral infection (HBV,HCV) 18) patients who are not applicable to this study judged by the medical doctor.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath